Cargando…

Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab

Fibrolamellar carcinoma (FLC) is a rare cancer of the liver that most commonly affects children and young adults. There is no clear standard of care for the disease, whose response to treatment seems to be very different from that of hepatocellular carcinoma. We present a case of FLC in a patient in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berger, Raanan, Dinstag, Gal, Tirosh, Omer, Schiff, Eyal, Kleiner, David, Aldape, Kenneth D, Ruppin, Eytan, Beker, Tuvik, Kurzrock, Razelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743402/ https://www.ncbi.nlm.nih.gov/pubmed/36600603 http://dx.doi.org/10.1136/jitc-2022-005620

Ejemplares similares

Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome
por: Dinstag, Gal, et al.
Publicado: (2023)

In vitro and in vivo identification of clinically approved drugs that modify ACE2 expression
por: Sinha, Sanju, et al.
Publicado: (2020)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma
por: Asher, Nethanel, et al.
Publicado: (2020)

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
por: Potluri, Ravi, et al.
Publicado: (2019)

Nivolumab plus ipilimumab in the treatment of advanced melanoma
por: Tsai, Katy K., et al.
Publicado: (2015)

Severe Gastritis after Administration of Nivolumab and Ipilimumab
por: Nishimura, Yoshito, et al.
Publicado: (2018)

Ipilimumab/nivolumab: Diffuse pneumonitis: case report
Publicado: (2020)

Ipilimumab and nivolumab for recurrent neuroendocrine cervical carcinoma
por: Towner, Mary, et al.
Publicado: (2022)

Sexual selection and the evolution of obligatory sex
por: Hadany, Lilach, et al.
Publicado: (2007)

Prediction of cancer treatment response from histopathology images through imputed transcriptomics
por: Hoang, Danh-Tai, et al.
Publicado: (2023)

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis
por: Marchetti, Paolo, et al.
Publicado: (2020)

Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis
por: Brastianos, Priscilla K., et al.
Publicado: (2021)

Adverse events induced by nivolumab and ipilimumab combination regimens
por: Somekawa, Kohei, et al.
Publicado: (2022)

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
por: Shitara, Kohei, et al.
Publicado: (2022)

Ipilimumab/nivolumab/tozinameran: Various toxicities: case report
Publicado: (2022)

Combined Nivolumab and Ipilimumab in Octogenarian and Nonagenarian Melanoma Patients
por: Reichert, Constance, et al.
Publicado: (2023)

Pathologic Complete Response to Neoadjuvant Nivolumab/Ipilimumab in a Patient with Metastatic Renal Cell Carcinoma
por: Peak, Taylor C., et al.
Publicado: (2020)

REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study
por: Vauchier, Charles, et al.
Publicado: (2022)

Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma
por: Gupta, Mehul, et al.
Publicado: (2023)

Sequential Therapy with Nivolumab Followed by Ipilimumab Induces Complete Response in Metastatic Melanoma of the Lung but with Severe Hepatotoxicities
por: Furudate, Sadanori, et al.
Publicado: (2016)

A Pathological Complete Response to the Combination of Ipilimumab and Nivolumab in a Patient with Metastatic Renal Cell Carcinoma
por: Studentova, Hana, et al.
Publicado: (2022)

Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy
por: Suozzi, Kathleen C., et al.
Publicado: (2016)

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy
por: Tan, Irena, et al.
Publicado: (2018)

Ipilimumab/nivolumab: Immune-related pneumonitis: 2 case reports
Publicado: (2020)

Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced Malignancies
por: Zhang, Jason, et al.
Publicado: (2019)

Ipilimumab/nivolumab/tozinameran: Severe necrotizing myopathy: case report
Publicado: (2022)

Cabozantinib/ipilimumab/nivolumab interaction: Haemophagocytic lymphohistiocytosis: case report
Publicado: (2021)

Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms
por: Al-Toubah, T., et al.
Publicado: (2021)

Ipilimumab/nivolumab/tozinameran: Acute myocarditis: 3 case reports
Publicado: (2022)

Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
por: Zhou, Shi, et al.
Publicado: (2019)

A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC
por: Lai, Gillianne G.Y., et al.
Publicado: (2022)

Complete response of metastatic renal cell carcinoma with inferior vena cava tumor thrombus to nivolumab plus ipilimumab
por: Hayashida, Michikata, et al.
Publicado: (2022)

Complete remission of brain metastases in renal cell carcinoma treated with axitinib after failure with nivolumab and ipilimumab treatment
por: Takayama, Koichiro, et al.
Publicado: (2022)

Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab
por: Hantel, Andrew, et al.
Publicado: (2018)

Excellent Response to Nivolumab and Ipilimumab in Metastatic Gastroesophageal Junction Squamous Carcinoma
por: Sadagopan, Narayanan, et al.
Publicado: (2019)

Lung brain metastasis pseudoprogression after nivolumab and ipilimumab combination treatment
por: Melian, Marcos, et al.
Publicado: (2018)

Eosinophilic airway inflammation and eosinophilic chronic rhinosinusitis during nivolumab and ipilimumab
por: Watanabe, Hirofumi, et al.
Publicado: (2020)

Population Pharmacokinetics of Ipilimumab in Combination With Nivolumab in Patients With Advanced Solid Tumors
por: Sanghavi, Kinjal, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_p8216725b5qtb4fdfdlb8eq0tf